Matches in SemOpenAlex for { <https://semopenalex.org/work/W2916974209> ?p ?o ?g. }
- W2916974209 endingPage "344" @default.
- W2916974209 startingPage "332" @default.
- W2916974209 abstract "Multiple myeloma (MM) is a plasma cell malignancy characterized by impaired immune surveillance mechanisms, such as altered antibody production, dysregulation of T cell and natural killer cell proliferation and activation, disruption of antigen presentation processes, and upregulation of checkpoint and immunosuppressive mediators. New and emerging immunotherapeutic agents, such as chimeric antigen receptor (CAR)-engineered T-cell therapies, vaccines, antibody-based therapy, and checkpoint inhibitors, have been developed as a means to target evasion tactics of MM. Herein we summarize the proceedings of “Immunotherapy in Multiple Myeloma: Accelerating on the Path to the Patient,” a workshop held in Havana, Cuba, with contributions from 18 expert hematologic oncologists from the United States, European Union, and Cuba, as well as patient advocacy and industry representatives. The goal of the workshop was to evaluate and discuss key topics and issues regarding development and use of immunotherapies in MM and to collaborate on improving patient outcomes. Clinical significance of recent advances in immunotherapies in MM were discussed, in addition to their current status and therapeutic potential, key issues from various regional perspectives, and opportunities for collaboration to improve MM patient outcomes. In this review we summarize expert presentations on cellular (CAR T cell, allogeneic stem cell transplantation, and vaccine) therapies, antibody-based (daratumumab, elotuzumab, checkpoint inhibitor, anti-cluster of differentiation 28 antibody) therapies, genomics and immunotherapy, and biomarkers of response." @default.
- W2916974209 created "2019-03-02" @default.
- W2916974209 creator A5002786000 @default.
- W2916974209 creator A5004257186 @default.
- W2916974209 creator A5007447330 @default.
- W2916974209 creator A5012606069 @default.
- W2916974209 creator A5016246851 @default.
- W2916974209 creator A5016626239 @default.
- W2916974209 creator A5023152679 @default.
- W2916974209 creator A5023276777 @default.
- W2916974209 creator A5035811221 @default.
- W2916974209 creator A5036677725 @default.
- W2916974209 creator A5045740077 @default.
- W2916974209 creator A5053904944 @default.
- W2916974209 creator A5077897003 @default.
- W2916974209 date "2019-06-01" @default.
- W2916974209 modified "2023-09-30" @default.
- W2916974209 title "Immunotherapy in Multiple Myeloma: Accelerating on the Path to the Patient" @default.
- W2916974209 cites W1498931318 @default.
- W2916974209 cites W1585625390 @default.
- W2916974209 cites W1647507681 @default.
- W2916974209 cites W1877911682 @default.
- W2916974209 cites W1902692042 @default.
- W2916974209 cites W1911679611 @default.
- W2916974209 cites W1971522146 @default.
- W2916974209 cites W1974656498 @default.
- W2916974209 cites W1982488143 @default.
- W2916974209 cites W1983923363 @default.
- W2916974209 cites W1987849309 @default.
- W2916974209 cites W2008832743 @default.
- W2916974209 cites W2015173973 @default.
- W2916974209 cites W2029570799 @default.
- W2916974209 cites W2031102381 @default.
- W2916974209 cites W2046408556 @default.
- W2916974209 cites W2049553585 @default.
- W2916974209 cites W2051810777 @default.
- W2916974209 cites W2052639059 @default.
- W2916974209 cites W2059142229 @default.
- W2916974209 cites W2059581635 @default.
- W2916974209 cites W2063939064 @default.
- W2916974209 cites W2067351018 @default.
- W2916974209 cites W2079278201 @default.
- W2916974209 cites W2080218360 @default.
- W2916974209 cites W2085918734 @default.
- W2916974209 cites W2086735887 @default.
- W2916974209 cites W2087025602 @default.
- W2916974209 cites W2089135124 @default.
- W2916974209 cites W2099570622 @default.
- W2916974209 cites W2104195581 @default.
- W2916974209 cites W2104347254 @default.
- W2916974209 cites W2113259749 @default.
- W2916974209 cites W2115619738 @default.
- W2916974209 cites W2120227082 @default.
- W2916974209 cites W2122262316 @default.
- W2916974209 cites W2123895023 @default.
- W2916974209 cites W2128192762 @default.
- W2916974209 cites W2128878080 @default.
- W2916974209 cites W2134168744 @default.
- W2916974209 cites W2136800142 @default.
- W2916974209 cites W2141502099 @default.
- W2916974209 cites W2149390157 @default.
- W2916974209 cites W2150997370 @default.
- W2916974209 cites W2153147430 @default.
- W2916974209 cites W2155535356 @default.
- W2916974209 cites W2156353875 @default.
- W2916974209 cites W2159773146 @default.
- W2916974209 cites W2160088281 @default.
- W2916974209 cites W2161702482 @default.
- W2916974209 cites W2169288585 @default.
- W2916974209 cites W2169846247 @default.
- W2916974209 cites W2180685301 @default.
- W2916974209 cites W2182681254 @default.
- W2916974209 cites W2198093519 @default.
- W2916974209 cites W2201190784 @default.
- W2916974209 cites W2201379305 @default.
- W2916974209 cites W2229483068 @default.
- W2916974209 cites W2230441773 @default.
- W2916974209 cites W2255051823 @default.
- W2916974209 cites W2293531514 @default.
- W2916974209 cites W2294395959 @default.
- W2916974209 cites W2299181842 @default.
- W2916974209 cites W2329974159 @default.
- W2916974209 cites W2400276917 @default.
- W2916974209 cites W2465860350 @default.
- W2916974209 cites W2471662063 @default.
- W2916974209 cites W2486629951 @default.
- W2916974209 cites W2494443970 @default.
- W2916974209 cites W2511571730 @default.
- W2916974209 cites W2512106959 @default.
- W2916974209 cites W2527905628 @default.
- W2916974209 cites W2528329272 @default.
- W2916974209 cites W2537387853 @default.
- W2916974209 cites W2543537089 @default.
- W2916974209 cites W2548694234 @default.
- W2916974209 cites W2553693801 @default.
- W2916974209 cites W2554479252 @default.
- W2916974209 cites W2557336488 @default.
- W2916974209 cites W2559594954 @default.